TULSA reduces tumor volume and PSA levels, improving urinary and sexual function in prostate cancer patients. Five-year TACT study data shows 80% of patients had no significant disease after one year, ...
MINNEAPOLIS and ATLANTA, April 16, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately held medical device company, today announced the continued expansion of its U.S. commercial launch with the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Minimally invasive transperineal laser ablation (TPLA) of the prostate appears effective for benign prostatic hyperplasia (BPH), according to a review published online Sept. 21 in Therapeutic Advances ...
Francis’ ongoing VAPOR 2 single-arm study aims to support a 510(k) application for Vanquish at the FDA this July, with one-year data from 235 patients diagnosed with localized, intermediate-risk ...
New distribution agreement positions TULSA-PRO within the iMRI Suite offering through Cook Medical’s Copernicus™ program, expanding Profound’s commercial reach. Profound ret ...
Francis Medical's Vanquish wields water vapor to overcome some of the limitations of traditional thermal ablation by applying high pressure in 10-second bursts through a catheter. (Francis Medical) ...
The global tumor ablation market is valued at USD 1.04 billion in 2026 and is projected to reach USD 1.8 billion by 2031, ...
Prostate cancer patients may soon have a new option to treat their disease: laser heat. UCLA researchers have found that focal laser ablation - the precise application of heat via laser to a tumor - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results